Supplementary
0.61  0.00 0.55  0.03 Male db/db mice (~ 3-month-old) that have been administrated with 0.5% methylcellulose (n=4) or G5 (5mg/kg in 0.5% methylcellulose, n=5) via oral garage for 14 days. Supplementary Figure 1 . Toxicity tests of 4548-G05 (A) MTT assay of HepG2 cells that have been treated with various concentrations of 4548-G05 for 24 h (**, P<0.01, one-way ANOVA, n=3). (B) Comet assay of HepG2 cells that have been treated with etoposide (50 M), 4548-G05 (10 M) or another anti-diabetic naphtoquinone (5,8-diacetyloxy-2,3-dichloro-1,4-naphthoquinone or DDN, 10 M) for 24 h (**, P<0.01, one-way ANOVA, n=3). (C) Micronucleus assay of HepG2 cells that have been treated with benzo[a]pyrene [B(a)P] (50 M), 4548-G05 (10 M) or another anti-diabetic naphtoquinone (5,8-diacetyloxy-2,3-dichloro-1,4-naphthoquinone or DDN, 10 M) for 24 h (**, P<0.01, one-way ANOVA, n=3). Figure 2 . 4548-G05 does no inhibit PTP activity. (A) 4548-G05 does not suppress PTP1B activity in vitro. 1,2-NQ (10, 100 M), different concentrations of 4548-G05 or DMSO (control) were incubated with recombinant PTP1B (0.4 g) and 4 mM pNPP for 30 min at 37 C. The dephosphorylation of pNPP was expressed as a percentage of the initial activity (*, P<0.05; **, P<0.01; n=3, one-way ANOVA versus control). (B) 4548-G05 does no inhibit the total PTP activity in cells. Serum-starved CHO-IR cells were exposed to DMSO (control), 1,2-NQ (20, 50 M) or different concentrations of 4548-G05 for 20 min. PTP activity in the cell lysates was determined using pNPP as the substrate. Dephosphorylation of pNPP was expressed as a percentage of the initial activity ( **, p<0.01; n=3, one-way ANOVA versus control). Figure 6 . Insulin binding induces a disorder-to-order transition in the IR-ECD αCT domain. (A) IR ECD (PDB ID: 2DTG; residues 4-651, 755-909) depicted as a cartoon with a transparent molecular surface. Residues 652-754 that are critical for insulin binding were not present in the deposited structure and their position is approximated with a dashed line. Protection factors generated from differential HDX experiments comparing the apo vs holo IR-ECD are mapped to protein according to the legend with strongest protection upon insulin binding indicated in dark blue. (B) Close up view of the insulin binding site showing strong protection for IR residues 705-715 (dark blue), 341-354, 376-382, and 487-502 . Moderate protection is observed for residues 1-12, 34-56, 476-481. The high-resolution structure of the IR-ECD (residues 4-711) and αCT domain (residues 704-719) in complex with insulin (PDB 3W11) shows remarkable agreement of the observed protection and the known insulin binding surface. Figure 7 . Proposed binding model of 4548-G05 with IR. (A) In silico analysis using AutoDock Vina suggests that 4548-G05 docks on the hinge region between the CR and L2 domains of IR. (B) Protein surface for the binding pocket of 4548-G05. The suggested amino acid residues of IR involved in 4548-G05 binding are numbered.

